Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02359227 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Cenderitide in Stable Chronic Heart Failure
A Phase 2 study, sponsored by Capricor.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT02359227 is a Phase 2 study that has completed, run by Capricor. The registered enrollment target is 14 participants.
The verdict
NCT02359227, a Phase 2 study, has completed, sponsored by Capricor.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
Planned enrollment is approximately twelve subjects with stable chronic heart failure. Enrolled subjects will receive up to eight sequential days of continuous, stepwise, dose increasing, subcutaneous (SQ) infusions of open-label cenderitide via the Insulet Drug Delivery System. Planned infusion rates of cenderitide will be administered to subjects continuously during four, 48-hour infusion periods.
Interventions
- DRUG Cenderitide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-04-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02359227
The ClinicalTrials.gov registry entry for NCT02359227 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Capricor, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cenderitide is the first listed.
NCT02359227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02359227 about?
NCT02359227 is a clinical study titled "Safety Study of Cenderitide in Stable Chronic Heart Failure". Planned enrollment is approximately twelve subjects with stable chronic heart failure. Enrolled subjects will receive up to eight sequential days of continuous, stepwise, dose increasing, subcutaneous (SQ) infusions of open-label cenderitide via the Insulet Drug Delivery System. Planned infusion rat...
What is the current status of trial NCT02359227?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2015-01. Estimated completion is 2015-04-02.
What interventions are being tested in trial NCT02359227?
The interventions under investigation include: Cenderitide (DRUG).
Who is sponsoring clinical trial NCT02359227?
This trial is sponsored by Capricor, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.